CDC25C Protein Expression Correlates with Tumor Differentiation and Clinical Outcomes in Lung Adenocarcinoma
Esther Stern,
Guy Pines,
Li Or Lazar,
Gilad W. Vainer,
Nitzan Beltran,
Omri Dodi,
Lika Gamaev,
Ofir Hikri Simon,
Michal Abraham,
Hanna Wald,
Amnon Peled,
Ori Wald
Affiliations
Esther Stern
Gene Therapy Institute, Hadassah Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel
Guy Pines
Department of General Surgery, Kaplan Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Rehovot 76100, Israel
Li Or Lazar
Department of General Surgery, Kaplan Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Rehovot 76100, Israel
Gilad W. Vainer
Department of Pathology, Hadassah Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel
Nitzan Beltran
Department of Pathology, Kaplan Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Rehovot 76100, Israel
Omri Dodi
Department of Pathology, Kaplan Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Rehovot 76100, Israel
Lika Gamaev
Gene Therapy Institute, Hadassah Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel
Ofir Hikri Simon
Department of General Thoracic Surgery, Kaplan Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Rehovot 76100, Israel
Michal Abraham
Gene Therapy Institute, Hadassah Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel
Hanna Wald
Gene Therapy Institute, Hadassah Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel
Amnon Peled
Gene Therapy Institute, Hadassah Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel
Ori Wald
Gene Therapy Institute, Hadassah Hebrew University Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel
Given that, even after multimodal therapy, early-stage lung cancer (LC) often recurs, novel prognostic markers to help guide therapy are highly desired. The mRNA levels of cell division cycle 25C (CDC25C), a phosphatase that regulates G2/M cell cycle transition in malignant cells, correlate with poor clinical outcomes in lung adenocarcinoma (LUAD). However, whether CDC25C protein detected by immunohistochemistry can serve as a prognostic marker in LUAD is yet unknown. We stained an LC tissue array and a cohort of 61 LUAD tissue sections for CDC25C and searched for correlations between CDC25C staining score and the pathological characteristics of the tumors and the patients’ clinical outcomes. Clinical data were retrieved from our prospectively maintained departmental database. We found that high expression of CDC25C was predominant among poorly differentiated LUAD (p 1cm (p p = 0.03, median follow-up of 39 months) and with a trend for reduced overall survival (p = 0.08). Therefore, high expression of CDC25C protein in LUAD is associated with aggressive histological features and with poor outcomes. Larger studies are required to further validate CDC25C as a prognostic marker in LUAD.
